Vertaling van "activity of clinical " (Nederlands → Frans) :

TERMINOLOGIE

activator voor tandheelkundige polymerisatie
lampe de polymérisation dentaire/chirurgicale

IN-CONTEXT TRANSLATIONS

1. [PDF] De poster " Development, Implementation and Evaluation of the Activity of Clinical Pharmacy through the Results of 54 Pilot Projects" (R.
1. [PPT] Le poster " Development, Implementation and Evaluation of the Activity of Clinical Pharmacy through the Results of 54 Pilot Projects" (R.

21. Netwerk MFC : Development, Implementation and Evaluation of the Activity of Clinical Pharmacy through the Results of 54 Pilot Projects (PDF)
21. Réseau des Comités Médicopharmaceutiques : Development, Implementation and Evaluation of the Activity of Clinical Pharmacy through the Results of 54 Pilot Projects (PDF)

However, the figures do clearly show that there is a considerable number of early phase trials. There are 7 units in Belgium actively undertaking phase I clinical trials and a number of early phase trials are being conducted in centres where there is expertise in specific clinical areas.
However, the figures do clearly show that there is a considerable number of early phase trials. There are 7 units in Belgium actively undertaking phase I clinical trials and a number of early phase trials are being conducted in centres where there is expertise in specific clinical areas.

The FAMHP intends to significantly increase its involvement in the lifecycle of immunological medicines for veterinary use by providing scientific advice, evaluating applications for clinical trials in Belgium, adopting (co-)rapporteurships for CP, MRP and DCP for MA of vaccines for veterinary use and developing pharmacovigilance and inspection activities.
The FAMHP intends to significantly increase its involvement in the lifecycle of immunological medicines for veterinary use by providing scientific advice, evaluating applications for clinical trials in Belgium, adopting (co-)rapporteurships for CP, MRP and DCP for MA of vaccines for veterinary use and developing pharmacovigilance and inspection activities.

Advisory commission which is consulted e.g. in cases of non-availability of medicines Commission for the approval of institutions assigning preliminary approvals for scientific events Commission for the establishment of retail pharmacies and chambers of appeal (Frenchspeaking chamber and Dutch-speaking chamber) Commission for the recognition of pharmacists-clinical biologists Commission for the supervision of advertising for medicines for human use Evaluation commission for active implantable medical devices Evaluation commission for homeopathic medicines Evaluation commission for medical devices Evaluation commission for medicines for human use Evaluation commission for medicines for veterinary use Evaluation commission for traditional herbal medicines Pharmacopoeia commission
Advisory commission which is consulted e.g. in cases of non-availability of medicines Commission for the approval of institutions assigning preliminary approvals for scientific events Commission for the establishment of retail pharmacies and chambers of appeal (Frenchspeaking chamber and Dutch-speaking chamber) Commission for the recognition of pharmacists-clinical biologists Commission for the supervision of advertising for medicines for human use Evaluation commission for active implantable medical devices Evaluation commission for homeopathic medicines Evaluation commission for medical devices Evaluation commission for medicines for human use Evaluation commission for medicines for veterinary use Evaluation commission for traditional herbal medicines Pharmacopoeia commission

R&D improved 0.7 percentage points, mainly driven by phasing of clinical trial activities.
La R&D s’est améliorée de 0,7 point de pourcentage, essentiellement à la suite d’un étalement dans le temps des essais cliniques.

R&D improved 0.3 percentage points, mainly driven by phasing of clinical trial activities.
La R&D s’est améliorée de 0,3 point, essentiellement à la suite d’un étalement dans le temps des essais cliniques.

R&D increased 0.3 percentage points, mainly driven by phasing of clinical trial activities.
Recherche et développement s’est amélioré de 0,3 point, essentiellement à la suite d’un étalement des essais cliniques dans le temps.

The R&D (research and development) department of the FAMHP is responsible for the evaluation and approval of clinical research activities, ranging from the first “use” (concept) to extensive trials with medicines that are developed and carried out by university and other research centres and by the pharmaceutical industry.
The R&D (research and development) department of the FAMHP is responsible for the evaluation and approval of clinical research activities, ranging from the first “use” (concept) to extensive trials with medicines that are developed and carried out by university and other research centres and by the pharmaceutical industry.